Results 141 to 150 of about 8,191,811 (190)
Hybridoma Technologies for Antibody Production
Immunotherapy, 2011 Hybridoma technology features effective usage of innate functions of both immune cells and cancers, allowing production of hybridoma cells, which continuously generate monoclonal antibodies specific to antigens of interest. For standard generation of hybridoma cells, B lymphocytes must be somatically fused with myeloma cells using various technologies.
Masahiro, Tomita, Kanta, Tsumoto
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Methods in Molecular Biology, 2015
The generation of hybridoma cell lines by the fusion of splenocytes from immunized mice with immortal myeloma cells is a well-established method for the production of monoclonal antibodies. Although other methods have emerged as an effective alternative for the generation of monoclonal antibodies, the use of hybridoma technology remains a viable ...
Larry H Stanker, Robert M Hnasko
exaly +3 more sources
The generation of hybridoma cell lines by the fusion of splenocytes from immunized mice with immortal myeloma cells is a well-established method for the production of monoclonal antibodies. Although other methods have emerged as an effective alternative for the generation of monoclonal antibodies, the use of hybridoma technology remains a viable ...
Larry H Stanker, Robert M Hnasko
exaly +3 more sources
Hybridoma Technology for the Generation of Monoclonal Antibodies
Methods in Molecular Biology, 2012Hybridoma technology has long been a remarkable and indispensable platform for generating high-quality monoclonal antibodies (mAbs). Hybridoma-derived mAbs have not only served as powerful tool reagents but also have emerged as the most rapidly expanding class of therapeutic biologics. With the establishment of mAb humanization and with the development
Chonghui Zhang
exaly +3 more sources
Current state of the hybridoma technology
Journal of Clinical Immunology, 1990The first description of the hybridoma technology in 1975 seemed to hold enormous promise for the treatment of a variety of human disease. The ability to produce monoclonal antibodies led to the availability of large amounts of homogeneous and predictable preparations of antibody.
L, Pirofski +4 more
openaire +2 more sources
Advances in hybridoma preparation using electrofusion technology
Biotechnology Journal, 2022As a rapidly developing cell engineering technique, cell electrofusion has been increasingly applied in the field of hybridoma preparation in recent years. However, electrofusion is a certain degree of difficulty to completely replace the polyethylene glycol-mediated cell fusion.
Jiaqian Kou +3 more
openaire +2 more sources
Monoclonal Antibodies Based on Hybridoma Technology
Pharmaceutical Patent Analyst, 2013Based on the size and scope of the present global market for medicine, monoclonal antibodies (mAbs) have a very promising future, with applications for cancers through autoimmune ailments to infectious disease. Since mAbs recognize only their target antigens and not other unrelated proteins, pinpoint medical treatment is possible.
Hisanori, Yagami +3 more
openaire +2 more sources
Preconditions for Hybridoma Technology
1992Producing and harvesting antibodies necessitates experiments involving animals. Such experiments must conform with any regulations governing animal experimentation imposed by the state or the local authorities with the aim of protecting animals or restricting the use of animals. The aim of such laws is to respect life, and therefore to reduce as far as
A. Wiggenhauser +2 more
openaire +1 more source
Screening for weak monoclonal antibodies in hybridoma technology
Journal of Molecular Recognition, 1998As the interest in weak-affinity antibodies has been widened by their introduction to various analytical techniques such as HPLC, capillary electrophoresis and biosensors, there has been a need for new screening/monitoring methods. In this study, weak-affinity chromatography was adopted to screen/monitor directly for monoclonal antibodies in ascites ...
L, Leickt, A, Grubb, S, Ohlson
openaire +2 more sources